Drug Trial Radar · NCT00137111
Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia
Last checked: Nov 20, 2026Latest source record: Sep 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
501
Actual
Start
Jul 8, 2000
Primary completion
Nov 2010
Study completion Apr 2014
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Aug 29, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 months, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to estimate the overall event-free survival of children at least one year of age at diagnosis who are treated with risk-directed therapy and to monitor the molecular remission induction rate.
Conditions
- Lymphoblastic Leukemia, Acute
Interventions
Prednisone, Dexamethasone, Vincristine, DaunorubicinDrug
See Detailed Description sections for details on treatment interventions.
Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginaseDrug
See Detailed Description sections for details on treatment interventions.
Methotrexate, Cyclophosphamide, Cytarabine, EtoposideDrug
See Detailed Description sections for details on treatment interventions.
Mercaptopurine, ImatinibDrug
See Detailed Description sections for details on treatment interventions.
chemotherapy, intrathecal chemotherapyProcedure
See Detailed Description sections for details on treatment interventions.
steroid therapy, hematopoietic stem cell transplantationProcedure
See Detailed Description sections for details on treatment interventions.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Event-free Survival (EFS)Time frame: Median follow-up time (range) 5.6 (1.3 to 8.9) years
- Continuous Complete Remission Since Week 56 Therapy.Time frame: Median follow up time (range) 4.5 (1 to 7.8) years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
St Jude Children's Research Hospital
Memphis, Tennessee
Cook Children's Medical Center
Fort Worth, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.